Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses
Nazanin Nazari et al.
IMMUNOLOGY AND CELL BIOLOGY (2021)
The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy
Angelina Tjokrowidjaja et al.
ACTA ONCOLOGICA (2020)
Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer
Junmi Lu et al.
PLOS ONE (2020)
Prognostic significance of PI3K/AKT/mTOR signaling pathway members in clear cell renal cell carcinoma
Demin Fan et al.
PEERJ (2020)
The immunology of renal cell carcinoma
C. Marcela Diaz-Montero et al.
NATURE REVIEWS NEPHROLOGY (2020)
Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma
Yijiao Yuan et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
TISIDB: an integrated repository portal for tumor-immune system interactions
Beibei Ru et al.
BIOINFORMATICS (2019)
Targeting mTOR for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Cai Zhang et al.
CLINICAL CANCER RESEARCH (2019)
mTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications?
Azzurra Irelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance
Steffen Rausch et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
Peter Makhov et al.
MOLECULAR CANCER THERAPEUTICS (2018)
mTOR at the Transmitting and Receiving ends in Tumor immunity
Yakir Guri et al.
FRONTIERS IN IMMUNOLOGY (2018)
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients
Michalis Liontos et al.
WORLD JOURNAL OF UROLOGY (2017)
Targeted therapies for renal cell carcinoma
Edwin M. Posadas et al.
NATURE REVIEWS NEPHROLOGY (2017)
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening
Guangchun Han et al.
BMC GENOMICS (2017)
Treatment of renal cell carcinoma: Current status and future directions
Pedro C. Barata et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li et al.
CANCER RESEARCH (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
mTOR Signaling in Growth, Metabolism, and Disease (vol 168, pg 960, 2017)
Robert A. Saxton et al.
CELL (2017)
Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma
Zuohui Zhao et al.
TUMOR BIOLOGY (2016)
Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma
Rujuan Su et al.
HEPATOLOGY RESEARCH (2016)
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Fengju Chen et al.
CELL REPORTS (2016)
mTORC1-Dependent Metabolic Reprogramming Is a Prerequisite for NK Cell Effector Function
Raymond P. Donnelly et al.
JOURNAL OF IMMUNOLOGY (2014)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
TCPA: a resource for cancer functional proteomics data
Jun Li et al.
NATURE METHODS (2013)
Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma
Oussama M. Darwish et al.
UROLOGY (2013)
Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma
Kotaro Hirashima et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Differential effects of immuno suppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: Selective upregulation by rapamycin
Valeria Sordi et al.
TRANSPLANTATION (2006)
Share Paper
